Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

OxyContin Will Face Fewer Generics Following Patent Infringement Settlement

This article was originally published in The Pink Sheet Daily

Executive Summary

As part of settlement agreements with Purdue Pharma, Endo and Teva agree to stop selling generic versions of the pain medication.

You may also be interested in...



OxyContin Patent Settlement Could Mean No Generics Come 2008

Purdue reaches agreement with final generic manufacturer of extended-release oxycodone.

OxyContin Patent Settlement Could Mean No Generics Come 2008

Purdue reaches agreement with final generic manufacturer of extended-release oxycodone.

Endo To Launch Opana ER Oxymorphone With Two Risk Management Programs

The firm will add 220 sales reps to support the July launch of the extended-release and immediate-release opioid analgesics.

Related Content

Topics

UsernamePublicRestriction

Register

PS064762

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel